Flputnam Investment Management Co. Invests $8.96 Million in Gilead Sciences, Inc. $GILD

Key Points

• Flputnam Investment Management purchased a new $8.96 million stake in Gilead Sciences during the second quarter, while other institutions also added positions. Institutional investors now own 83.67% of the company.
• Gilead reported quarterly revenue of $7.80 billion, exceeding estimates of $7.40 billion, while adjusted loss per share was better than expected. Revenue increased 10.6% year over year, although the company posted negative margins and return on equity.
• Gilead declared a quarterly dividend of $0.82 per share, equivalent to a 2.4% annualized yield. Analysts maintain a “Moderate Buy” consensus with an average price target of $158.04, above the reported share price of $138.36.

Flputnam Investment Management Co. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 70,944 shares of the biopharmaceutical company's stock, valued at approximately $8,963,000.

A number of other hedge funds also recently made changes to their positions in GILD. Global Retirement Partners LLC bought a new position in Gilead Sciences during the 2nd quarter worth approximately $4,372,000. Alberta Investment Management Corp bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $55,842,000. SCS Capital Management LLC acquired a new stake in Gilead Sciences during the second quarter worth approximately $835,000. Silverlake Wealth Management LLC acquired a new stake in Gilead Sciences during the second quarter worth approximately $308,000. Finally, Centric Wealth Management bought a new stake in Gilead Sciences in the second quarter worth approximately $3,517,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $138.36 on Monday. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The company has a market cap of $171.56 billion, a PE ratio of -51.82 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a 50-day moving average of $130.11 and a 200-day moving average of $136.44.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the company earned $2.01 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post -0.53 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent analyst reports. Daiwa Securities Group dropped their price target on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a research note on Wednesday, August 5th. Weiss Ratings lowered shares of Gilead Sciences from a "buy (b-)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. Finally, Truist Financial reduced their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a report on Tuesday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $158.04.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can't import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares of the company's stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,000 shares of company stock valued at $6,568,860 in the last three months. 0.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source